KR100271382B1 - Human receptor h4-1bb - Google Patents

Human receptor h4-1bb Download PDF

Info

Publication number
KR100271382B1
KR100271382B1 KR1019997007048A KR19997007048A KR100271382B1 KR 100271382 B1 KR100271382 B1 KR 100271382B1 KR 1019997007048 A KR1019997007048 A KR 1019997007048A KR 19997007048 A KR19997007048 A KR 19997007048A KR 100271382 B1 KR100271382 B1 KR 100271382B1
Authority
KR
South Korea
Prior art keywords
receptor protein
protein
human
receptor
cells
Prior art date
Application number
KR1019997007048A
Other languages
English (en)
Inventor
Byoungs Kwon
Original Assignee
Indiana University Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22404839&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100271382(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Indiana University Foundation filed Critical Indiana University Foundation
Application granted granted Critical
Publication of KR100271382B1 publication Critical patent/KR100271382B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
KR1019997007048A 1993-09-16 1999-07-30 Human receptor h4-1bb KR100271382B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12279693A 1993-09-16 1993-09-16
PCT/US1994/010457 WO1995007984A1 (en) 1993-09-16 1994-09-15 Human receptor h4-1bb

Publications (1)

Publication Number Publication Date
KR100271382B1 true KR100271382B1 (en) 2000-11-15

Family

ID=22404839

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1019960701385A KR100244960B1 (ko) 1993-09-16 1994-09-15 인간 수용체 h4-1bb
KR1019997007048A KR100271382B1 (en) 1993-09-16 1999-07-30 Human receptor h4-1bb

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1019960701385A KR100244960B1 (ko) 1993-09-16 1994-09-15 인간 수용체 h4-1bb

Country Status (11)

Country Link
US (3) US8026353B2 (ko)
EP (1) EP0719329B1 (ko)
JP (2) JPH09503911A (ko)
KR (2) KR100244960B1 (ko)
AT (1) ATE454449T1 (ko)
AU (1) AU697482B2 (ko)
CA (2) CA2172165C (ko)
DE (1) DE69435261D1 (ko)
ES (1) ES2341631T3 (ko)
NZ (1) NZ273838A (ko)
WO (1) WO1995007984A1 (ko)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6362325B1 (en) 1988-11-07 2002-03-26 Advanced Research And Technology Institute, Inc. Murine 4-1BB gene
US6303121B1 (en) 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
US7138500B1 (en) 1993-05-07 2006-11-21 Immunex Corporation Antibodies to human 4-1BB
US7211259B1 (en) 1993-05-07 2007-05-01 Immunex Corporation 4-1BB polypeptides and DNA encoding 4-1BB polypeptides
CA2172165C (en) 1993-09-16 2003-12-02 Byoung S. Kwon Human receptor h4-1bb
ATE226641T1 (de) * 1995-04-08 2002-11-15 Lg Chemical Ltd Humaner 4-1bb spezifischer humaner antikörper und diesen produzierende zellinie
WO1997033898A1 (en) * 1996-03-15 1997-09-18 Human Genome Sciences, Inc. Human 4-1bb receptor splicing variant
US5874240A (en) * 1996-03-15 1999-02-23 Human Genome Sciences, Inc. Human 4-1BB receptor splicing variant
WO1998016249A1 (en) * 1996-10-11 1998-04-23 Bristol-Myers Squibb Company Methods and compositions for immunomodulation
CZ20003238A3 (cs) * 1998-07-15 2001-10-17 Merckle Gmbh Pouľití CD137 pro podporu proliferace periferních monocytů
CA2392477A1 (en) 1999-11-30 2001-06-07 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
US7651686B2 (en) 2001-10-09 2010-01-26 Mayo Foundation For Medical Education And Research Enhancement of immune responses by 4-1bb-binding agents
CA2492561A1 (en) * 2002-07-15 2004-01-22 Mayo Foundation For Medical Education And Research Treatment and prophylaxis with 4-1bb-binding agents
AU2003290059A1 (en) * 2002-12-16 2004-07-09 Herbert Schwarz Use of cd137 antagonists for the treatment of tumors
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
US20070253961A1 (en) * 2004-06-09 2007-11-01 Ulsan Industrial Education Foundation Pharmaceutical Composition Comprising the Anti-4-1Bb Antibody for Treating or Preventing Rheumatoid Arthritis
AU2005295038B2 (en) 2004-10-06 2012-05-17 Mayo Foundation For Medical Education And Research B7-H1 and methods of diagnosis, prognosis, and treatment of cancer
US20060182744A1 (en) * 2005-02-15 2006-08-17 Strome Scott E Anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof
US20080019905A9 (en) * 2005-02-18 2008-01-24 Strome Scott E Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection
EP2388272A1 (en) * 2005-10-21 2011-11-23 GTC Biotherapeutics, Inc. Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use
WO2009134389A2 (en) * 2008-05-01 2009-11-05 Gtc Biotherapeutics, Inc. An anti-cd137 antibody as an agent in the treatment of inflammatory conditions
WO2010042433A1 (en) 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
JPWO2011149025A1 (ja) * 2010-05-28 2013-07-25 株式会社上野忠 経口用体温上昇剤
JP5947311B2 (ja) * 2010-12-09 2016-07-06 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 癌を治療するためのキメラ抗原受容体改変ｔ細胞の使用
US9402865B2 (en) 2011-01-18 2016-08-02 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cancer
US9302005B2 (en) 2013-03-14 2016-04-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
US10259875B2 (en) 2013-10-01 2019-04-16 Mayo Foundation For Medical Education And Research Methods for treating cancer in patients with elevated levels of BIM
MY191608A (en) 2014-04-07 2022-07-01 Novartis Ag Treatment of cancer using anti-cd19 chimeric antigen receptor
US10302653B2 (en) 2014-05-22 2019-05-28 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti B7-H1 antibodies
US10517875B2 (en) 2014-07-23 2019-12-31 Mayo Foundation for Medical Engineering and Research Targeting DNA-PKcs and B7-H1 to treat cancer
BR112017021500A2 (pt) 2015-04-08 2018-09-25 Novartis Ag terapias com cd20, terapias com cd22 e terapias de combinação com uma célula que expressa (car) receptor de antígeno quimérico de cd19
US10875923B2 (en) 2015-10-30 2020-12-29 Mayo Foundation For Medical Education And Research Antibodies to B7-H1
EP3523331A1 (en) 2016-10-07 2019-08-14 Novartis AG Chimeric antigen receptors for the treatment of cancer
SG10202102897PA (en) 2017-01-20 2021-04-29 Magenta Therapeutics Inc Compositions and methods for the depletion of cd137+ cells
JP7402521B2 (ja) 2017-07-11 2023-12-21 コンパス セラピューティクス リミテッド ライアビリティ カンパニー ヒトｃｄ１３７に結合するアゴニスト性抗体およびその使用
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
EP3713961A2 (en) 2017-11-20 2020-09-30 Compass Therapeutics LLC Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
CA3169910A1 (en) 2020-02-28 2021-09-02 Shanghai Henlius Biotech, Inc. Anti-cd137 constructs, multispecific antibody and uses thereof
CA3169939A1 (en) 2020-02-28 2021-09-02 Jie Xue Anti-cd137 construct and use thereof
CN114605541B (zh) * 2021-08-26 2023-08-29 北京大学深圳研究生院 一种抗4-1bb纳米抗体、编码基因及应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560649A (en) 1981-10-15 1985-12-24 Cornell Research Foundation Assaying for hLH or hCG with immobilized hormone receptors
US4837306A (en) * 1985-02-25 1989-06-06 The Ontario Cancer Institute Method for selecting hybridomas producing antibodies specific to the P-glycoprotein cell suface antigen and a cDNA clone encoding the C-terminal portion of the antigen
US6303121B1 (en) * 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
US5350836A (en) 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US7138500B1 (en) * 1993-05-07 2006-11-21 Immunex Corporation Antibodies to human 4-1BB
US7211259B1 (en) * 1993-05-07 2007-05-01 Immunex Corporation 4-1BB polypeptides and DNA encoding 4-1BB polypeptides
US5674704A (en) 1993-05-07 1997-10-07 Immunex Corporation Cytokine designated 4-IBB ligand
CA2172165C (en) 1993-09-16 2003-12-02 Byoung S. Kwon Human receptor h4-1bb
ATE226641T1 (de) * 1995-04-08 2002-11-15 Lg Chemical Ltd Humaner 4-1bb spezifischer humaner antikörper und diesen produzierende zellinie

Also Published As

Publication number Publication date
AU7729494A (en) 1995-04-03
JPH09503911A (ja) 1997-04-22
KR100244960B1 (ko) 2000-02-15
AU697482B2 (en) 1998-10-08
ES2341631T3 (es) 2010-06-23
US20020168719A1 (en) 2002-11-14
ATE454449T1 (de) 2010-01-15
CA2429027A1 (en) 1995-03-23
EP0719329B1 (en) 2010-01-06
EP0719329A1 (en) 1996-07-03
NZ273838A (en) 1997-09-22
WO1995007984A1 (en) 1995-03-23
DE69435261D1 (de) 2010-02-25
CA2172165C (en) 2003-12-02
JP2006149389A (ja) 2006-06-15
US8026353B2 (en) 2011-09-27
US20080312418A1 (en) 2008-12-18
CA2172165A1 (en) 1995-03-23
US20070117161A1 (en) 2007-05-24
CA2429027C (en) 2011-04-05

Similar Documents

Publication Publication Date Title
KR100271382B1 (en) Human receptor h4-1bb
Mechtersheimer et al. Expression of the natural killer cell-associated antigens CD56 and CD57 in human neural and striated muscle cells and in their tumors
Lane et al. Soluble CD40 ligand can replace the normal T cell-derived CD40 ligand signal to B cells in T cell-dependent activation.
US5747037A (en) Anti-GP39 antibodies
Luescher et al. CD8 modulation of T-cell antigen receptor–ligand interactions on living cytotoxic T lymphocytes
AU784634B2 (en) B7-H1, a novel immunoregulatory molecule
CA2246352A1 (en) Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith
US5869049A (en) Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
Bonnefoy et al. The low-affinity receptor for IgE (CD23) on B lymphocytes is spatially associated with HLA-DR antigens.
Wade et al. Structural compartmentalization of MHC class II signaling function
Bikah et al. A role for CD5 in cognate interactions between T cells and B cells, and identification of a novel ligand for CD5.
KR940007179A (ko) 시디40 (cd40)을 위한 수용성 리간드
US20100015153A1 (en) Novel Triggering Receptor Involved in Natural Cytotoxicity Mediated by Human Natural Killer Cells and Antibodies That Identify the Same
CA2146895A1 (en) Ctla4/cd28ig hybrid fusion proteins
Lanier et al. Natural killer cells
NZ527297A (en) Immunosuppression by blocking T cell co-stimulation signal 2 (B7/CD28 interaction)
JP2004537500A (ja) 腫瘍の増殖の阻害および免疫応答の増強のための方法および組成物
Johnson et al. Accessory molecules involved in antigen-mediated cytolysis and lymphokine production by cytotoxic T lymphocyte subsets. I. Identification of functions for the T cell surface molecules Ly-6C and Thy-1.
Koide et al. Augmentation of Human Natural Cell-Mediated Cytotoxicity by a Soluble Factor: I. Production of N-Cell-Activating Factor (NAF)
EP1240326A2 (en) Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells, and antibodies that identify the same
Bromberg The biology of CD2: adhesion, transmembrane signal, and regulatory receptor of immunity
Kumamoto et al. Monoclonal antibody specific for TIRC7 induces donor-specific anergy and prevents rejection of cardiac allografts in mice
Faassen et al. Cross-linking cell surface class II molecules stimulates Ig-mediated B cell antigen processing.
Nieland et al. AT cell lymphoma can provide potent co-stimulatory effects to T cells that are not mediated by B7-1, B7-2, CD40, HSA or CD70
AU678532C (en) Methods for inducing antigen-specific T cell tolerance

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20120806

Year of fee payment: 13

FPAY Annual fee payment

Payment date: 20130808

Year of fee payment: 14

FPAY Annual fee payment

Payment date: 20140805

Year of fee payment: 15

EXPY Expiration of term